Mirum Pharmaceuticals on Monday said its experimental hepatitis drug reduced levels of the virus in patients, meeting the main goal of a late-stage study.
Mirum Pharmaceuticals is testing brelovitug, an experimental monoclonal antibody designed to target the hepatitis B surface antigen, a protein found on the surface of the virus. The company is evaluating the treatment for chronic hepatitis delta virus, a rare liver infection that can only occur in people already infected with hepatitis B.
The disease often leads to severe symptoms and can progress to significant liver damage and even death. According to Mirum’s estimates, about 230,000 people in the US and Europe are living with hepatitis delta.
In the study, brelovitug showed promising results at 24 weeks. Fifty-six percent of patients who received 300 milligrams and 45% of patients who received 900 milligrams achieved both a reduction in hepatitis D virus levels and normal liver enzyme levels.
By comparison, 0% of patients in the delayed treatment group reached those endpoints. Mirum said the treatment was well tolerated across all dose groups, and the safety profile was consistent with previously reported data.
The company plans to present the full results from the study at an upcoming medical congress. Mirum also expects to submit a marketing application for brelovitug to the US FDA in the first half of 2027.
